Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
17 Giugno 2024 - 2:00PM
Scorpius Holdings, Inc (NYSE
American: SCPX) (“Scorpius” or “the
Company”), an integrated contract development and manufacturing
organization (“CDMO”), today reported that it received notice from
the NYSE American of its determination to commence delisting
proceedings of the Company’s common stock from the exchange
pursuant to Section 1003(f)(v) of the NYSE American Company Guide
due to the low-selling price of the Company’s common stock. The
Company plans to appeal the determination to the Exchange’s Listing
Qualifications Panel, although there can be no assurance of a
successful outcome.
Scorpius CEO Jeff Wolf commented, “Despite
recent positive developments, the NYSE American has made the
unfortunate decision to suspend trading in our securities based on
our per-share price. We strongly disagree with the ruling and plan
to appeal. We look forward to providing further updates.”
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, Texas. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements such as the Company’s plans to appeal the determination
to the Exchange’s Listing Qualifications Panel and the outcome of
the appeal from current expectations include, among others, the
ability of the Company to successfully appeal the determination to
the Exchange’s Listing Qualifications Panel and have its common
stock remain listed on the NYSE American; the Company’s financing
needs, its cash balance being sufficient to sustain operations and
its ability to raise capital when needed, the Company’s ability to
leverage fixed costs and achieve long-term profitability; the
Company’s ability to obtain regulatory approvals or to comply with
ongoing regulatory requirements, regulatory limitations relating to
the Company’s ability to successfully promote its services and
compete as a pure-play CDMO, and other factors described in the
Company’s annual report on Form 10-K for the year ended December
31, 2023, subsequent quarterly reports on Form 10-Qs and any other
filings the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017ir@scorpiusbiologics.com
Grafico Azioni Scorpius (AMEX:SCPX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Scorpius (AMEX:SCPX)
Storico
Da Giu 2023 a Giu 2024